MX2021013943A - Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. - Google Patents

Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.

Info

Publication number
MX2021013943A
MX2021013943A MX2021013943A MX2021013943A MX2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A MX 2021013943 A MX2021013943 A MX 2021013943A
Authority
MX
Mexico
Prior art keywords
lag
administration
dosage regimes
bispecific antibody
regimes
Prior art date
Application number
MX2021013943A
Other languages
English (en)
Inventor
Michelle Morrow
Fiona Germaschewski
Daniel Gliddon
Kin-Mei Leung
Cristian Gradinaru
Christopher Shepherd
Josefin-Beate Holz
Louis Kayitalire
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of MX2021013943A publication Critical patent/MX2021013943A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La solicitud se refiere a pautas posológicas para la administración de una molécula de anticuerpo que se une al ligando 1 de muerte programada (PD-L1) y al gen 3 de activación de linfocitos (LAG-3) y a su uso médico en el tratamiento del cáncer en pacientes humanos.
MX2021013943A 2019-05-14 2020-05-14 Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. MX2021013943A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
MX2021013943A true MX2021013943A (es) 2022-01-04

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013943A MX2021013943A (es) 2019-05-14 2020-05-14 Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.

Country Status (12)

Country Link
US (1) US20220275092A1 (es)
EP (1) EP3969477A1 (es)
JP (1) JP2022533578A (es)
KR (1) KR20220008316A (es)
CN (1) CN114206939A (es)
AU (1) AU2020275209A1 (es)
BR (1) BR112021022831A2 (es)
CA (1) CA3139003A1 (es)
IL (1) IL287979A (es)
MX (1) MX2021013943A (es)
SG (1) SG11202112136RA (es)
WO (1) WO2020229626A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3213796A1 (en) * 2021-03-31 2022-10-06 Merus N.V. Novel multispecific antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017283181A1 (en) 2016-06-20 2019-01-03 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
AU2018277559A1 (en) * 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
EP4306542A3 (en) * 2017-05-30 2024-04-17 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors

Also Published As

Publication number Publication date
EP3969477A1 (en) 2022-03-23
BR112021022831A2 (pt) 2022-01-18
IL287979A (en) 2022-01-01
US20220275092A1 (en) 2022-09-01
WO2020229626A1 (en) 2020-11-19
CA3139003A1 (en) 2020-11-19
KR20220008316A (ko) 2022-01-20
JP2022533578A (ja) 2022-07-25
AU2020275209A1 (en) 2021-12-23
SG11202112136RA (en) 2021-11-29
CN114206939A (zh) 2022-03-18

Similar Documents

Publication Publication Date Title
Dillon et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
Balagula et al. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
PH12017502270A1 (en) Combination therapy for the treatment of cancer
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
Mannas et al. Long-term treatment with temozolomide in malignant glioma
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
MX2021013943A (es) Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1.
PH12020551447A1 (en) Antibodies
Morris et al. Results of a 5-week schedule of modern total skin electron beam radiation therapy
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
Coskun Benlidayi et al. Comparative short-term effectiveness of ibuprofen gel and cream phonophoresis in patients with knee osteoarthritis
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
Dos Santos et al. Anti-leukemic activity of daratumumab in acute myeloid leukemia cells and patient-derived xenografts
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
AU2021318589A1 (en) Use of CD44 antibody in preparation of medicine for treating Parkinson's disease
MX2023007178A (es) Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
MX2023002278A (es) Uso de un anticuerpo anti-pd-1 y un farmaco antineoplasico citotoxico en el tratamiento del cancer de pulmon no microcitico.
Nagai et al. The preclinical activities of PTC596, a novel tubulin binding agent that down-regulates BMI1, alone and in combination with bortezomib in multiple myeloma
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
Kozaric et al. The comparison of efficacy between generic and branded imatinib in achievement of overall survival and cytogenetic responses in CML patients in Bosnia and Herzegovina